- AMRN shares are up almost 30% last month, likely due in part to AMRN's success in keeping generics to 11% market share and the imminent European launch.
- AMRN share price is still near its lows since it reported its REDUCE-IT data in 2018.
- As the Nevada ANDA litigation ends as an AMRN loss, a generic (and pharma benefits managers) have filed anti-trust lawsuits against AMRN.
- AMRN has a chance at winning its Delaware patent infringement lawsuit against Hikma and Health Net.
- There were a number of updates last month in the pending AMRN v. generic and relevant litigations, in AMRN's favor.
For further details see:
Amarin Stock Looks Attractive Despite U.S. Litigations